Ischemic Stroke Lab

Ischemia Care is a molecular diagnostics company that develops and commercializes blood-based tests to determine the cause of ischemic strokes. Operating through its commercial division, Ischemic Stroke Lab, the company utilizes a proprietary platform that analyzes RNA expression patterns in the blood to differentiate between stroke etiologies, such as cardioembolic or large artery atherosclerosis. Its lead product, ISCDx, is a CLIA-validated laboratory-developed test (LDT) designed to help clinicians identify the underlying cause of "cryptogenic" strokes, enabling more targeted secondary prevention and reducing hospital costs. The company's technology is supported by the BASE (Biomarkers of Acute Stroke Etiology) clinical trial, one of the largest prospective studies of its kind in stroke diagnostics.